We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management
Read MoreHide Full Article
DexCom Inc. (DXCM - Free Report) and MD Revolution recently announced their partnership, where Dexcom is likely to integrate its industry-leading continuous glucose monitoring (CGM) systems with MD Revolution’s remote care management.
Dexcom’s wearable devices pair with users' smartphones to monitor glucose levels. As a result of the partnership, patients' glucose monitoring data can now be made available to clinicians through MD Revolution’s care management platform, which is likely to empower clinicians to make informed decisions and provide better patient care.
Price Performance
Over the past six months, DXCM’s shares have gained 72.4% compared with the industry’s rise of 22.1%. The S&P 500 increased 17.1% in the same time frame.
Image Source: Zacks Investment Research
More on the News
MD Revolution offers a remote care management platform that seamlessly integrates with an ecosystem of EHRs, data partners, and devices to power comprehensive remote care for large practices, health systems and healthcare organizations. The company offers software as a service or an end-to-end program, along with a clinical care team to manage remote care as an extension of the practice.
MD Revolution powers programs for Chronic Care Management, Remote Patient Monitoring (RPM), Transitional Care Management, Annual Wellness Visits, and more.
The collaboration between Dexcom and MD Revolution is likely to be a good solution for providers looking for remote care management for CGM patients who want streamlined services, billing, and management under one cohesive remote care strategy.
This integration further strengthens MD Revolution’s scalable care management platform and ecosystem of integrated EHRs, data partners and devices that power the company’s remote care programs.
With the help of Dexcom's continuous glucose monitoring systems, patients can closely monitor their blood sugar levels. Patients can now proactively manage diabetes and other chronic illnesses at the same time by having access to clinical health coaches and real-time remote care thanks to the combination of RPM and CGM.
Industry Prospects
Per a report by MarketsandMarkets, the global digital diabetes management market was estimated to be $18.9 billion in 2023 and is expected to reach $35.8 billion by 2028 at a growth rate of 13.6%.
The market is being driven by escalating diabetes care solutions and technological developments that have made it possible to introduce highly adaptable solutions. Other significant drivers include the increasing popularity of the use of connected devices and apps as well as the growing adoption of cloud-based solutions.
Given the market potential, Dexcom’s collaboration with MD Revolution is likely to provide a significant boost to Dexcom’s business.
Notable Developments
DexCom recently introduced a new direct-to-Apple-Watch feature for its G7 continuous glucose monitor (CGM) users. With the new feature, G7 is likely to be the first CGM device that can link to Apple Watch directly, negating the requirement for an iPhone to be carried around.
Dexcom also announced the FDA clearance of its Stelo glucose biosensor, which is available over the counter to consumers without a prescription. Stelo's approval for non-prescription use would further facilitate this population's access to cutting-edge CGM technology.
In December 2023, Dexcom announced the Dexcom G7 CGM System connectivity with the t: slim X2 insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM.
Some other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Cencora, Inc. (COR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 58.3% compared with the industry’s 18.9% rise in the past year.
Cardinal Health, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 51.9% compared with the industry’s 3.2% rise in the past year.
Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 9.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.7%.
Cencora’s shares have rallied 51.5% compared with the industry’s 3.6% rise in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management
DexCom Inc. (DXCM - Free Report) and MD Revolution recently announced their partnership, where Dexcom is likely to integrate its industry-leading continuous glucose monitoring (CGM) systems with MD Revolution’s remote care management.
Dexcom’s wearable devices pair with users' smartphones to monitor glucose levels. As a result of the partnership, patients' glucose monitoring data can now be made available to clinicians through MD Revolution’s care management platform, which is likely to empower clinicians to make informed decisions and provide better patient care.
Price Performance
Over the past six months, DXCM’s shares have gained 72.4% compared with the industry’s rise of 22.1%. The S&P 500 increased 17.1% in the same time frame.
Image Source: Zacks Investment Research
More on the News
MD Revolution offers a remote care management platform that seamlessly integrates with an ecosystem of EHRs, data partners, and devices to power comprehensive remote care for large practices, health systems and healthcare organizations. The company offers software as a service or an end-to-end program, along with a clinical care team to manage remote care as an extension of the practice.
MD Revolution powers programs for Chronic Care Management, Remote Patient Monitoring (RPM), Transitional Care Management, Annual Wellness Visits, and more.
The collaboration between Dexcom and MD Revolution is likely to be a good solution for providers looking for remote care management for CGM patients who want streamlined services, billing, and management under one cohesive remote care strategy.
This integration further strengthens MD Revolution’s scalable care management platform and ecosystem of integrated EHRs, data partners and devices that power the company’s remote care programs.
With the help of Dexcom's continuous glucose monitoring systems, patients can closely monitor their blood sugar levels. Patients can now proactively manage diabetes and other chronic illnesses at the same time by having access to clinical health coaches and real-time remote care thanks to the combination of RPM and CGM.
Industry Prospects
Per a report by MarketsandMarkets, the global digital diabetes management market was estimated to be $18.9 billion in 2023 and is expected to reach $35.8 billion by 2028 at a growth rate of 13.6%.
The market is being driven by escalating diabetes care solutions and technological developments that have made it possible to introduce highly adaptable solutions. Other significant drivers include the increasing popularity of the use of connected devices and apps as well as the growing adoption of cloud-based solutions.
Given the market potential, Dexcom’s collaboration with MD Revolution is likely to provide a significant boost to Dexcom’s business.
Notable Developments
DexCom recently introduced a new direct-to-Apple-Watch feature for its G7 continuous glucose monitor (CGM) users. With the new feature, G7 is likely to be the first CGM device that can link to Apple Watch directly, negating the requirement for an iPhone to be carried around.
Dexcom also announced the FDA clearance of its Stelo glucose biosensor, which is available over the counter to consumers without a prescription. Stelo's approval for non-prescription use would further facilitate this population's access to cutting-edge CGM technology.
In December 2023, Dexcom announced the Dexcom G7 CGM System connectivity with the t: slim X2 insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM.
Price
price | Quote
Zacks Rank & Other Stocks to Consider
DXCM carries a Zacks Rank #2 (Buy) at present.
Some other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Cencora, Inc. (COR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 58.3% compared with the industry’s 18.9% rise in the past year.
Cardinal Health, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 51.9% compared with the industry’s 3.2% rise in the past year.
Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 9.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.7%.
Cencora’s shares have rallied 51.5% compared with the industry’s 3.6% rise in the past year.